EYAS AL MOUSA

Date Prepared: 2/ 2009

'Curriculum Vitae'

Name: Eyas N. Al-Mousa, M.D.

Current Position: Senior Interventional Cardiologist- Private Sector-9/2005 to present - Associate Clinical Professor. Jordan University Hospital. Amman,

Formerly- General Director . Al Istiklal Hospital( 5/2006-3/2008)

Address: P. O. Box: 13075 Jordan University Hospital Amman, Jordan 11942

Telephone number: 962-6-5001016 5001000( EXT 262) 962-777-963000 (mobile)

Fax Number: 962-6-5698833 E-Mail Addresses: eyasalmousa@hotmail.com ealmousa@istisharihospital,com eyas@eyasalmousa.com cardiology@istisharihospital.com

Education:

1988 M.B.B.S., University of Jordan, Amman, Jordan

1988-1989 Rotating Internship, University of Jordan Hospital 1989-1990 Resident in Medicine, University of Jordan Hospital 1990-1993 Resident in Medicine, Baylor College of Medicine Affiliated Hospitals (The Methodist Hospital, St Luke’s Episcopal Hospital, Ben Taub General Hospital and the Houston VA Medical Center). Houston, Texas. USA.

1993-1996 Clinical Fellow in Cardiology, University of Texas Affiliated Hospitals ( Hermann Hospital, LBJ General Hospital, MD Anderson Cancer Center, Houston Northwest Hospital and the Texas Heart Institute). Houston, Texas. USA 1996-1997 Clinical Fellow in Advanced Interventional Cardiology, Harvard Medical School, West Roxbury VA Medical Center/ Brigham and Women’s Hospital Program, Boston, Massachusetts. USA

Experience: 9 /1997- 9/2005 Director of Cardiology Associate Professor of Medicine and Cardiology Jordan University Hospital

1/2006-5/2006 Director of Medical Services. Al -Istiklal Hospital

1993 Diplomate, American Board of Internal Medicine 1996 Diplomate, Jordanian Board of Internal Medicine 1997 Diplomate, American Board of Cardiovascular Medicine 1998 Diplomate, Jordanian Board of Cardiovascular Medicine 2009 Certified Surveyor. Jordan Health Card Accreditation Council

Major Committee/Board Assignments:

1997 and 2003 Member of the National Committee for “Preventive Cardiology Guidelines” in Jordan. 1997-present Member of review board for Jordan Medical Journal and Damascus medical Journal 1998-Present Member of the Scientific/ Executive Cardiology Committee of the Jordanian Medical Council - Jordan Cardiology Board

1999 Member of the Scientific/ Executive Committee of Jordan Sport’s Medicine Council

2002 Member of Jordan University' President- appointed committee to reform Jordan University Hospital

2003 Editorial Board, Cardiology, The LANCET Middle East 2004 Executive and international editorial board, Pan Arab Medical Journal Chair, CPR committee. Jordan University Hospital

2005 Chair, cardiovascular committee of Jordan national drug formulary Professional Societies:

1990 American College Of Physicians 1993 American College Of Cardiology 2004 Jordanian Cardiac Society 2004 Jordan Lipid and Hypertension Society

Major Research Interests:

1. Mechanisms of LDL Oxidation 2. Utilization of Trans-esophageal Echocardiography in I.C.U. 3. Glycoprotein IIb/IIIa Role in Coronary Interventions 4. Newer Revascularization Devices 5. Assessment of Coronary Flow Using TIMI Frame Count Methods 6. Angiographic Predictors of Clinical Events in Interventional Cardiology 7. Coronary Ectasia in Jordan

Research Experience:

1993: Mechanisms of LDL Oxidation: Research Resident with M. Lenz, M.D. and J. Guytone, M.D. Role of monocyte-lipoxygenases in oxidative modification of LDL. Lipid research laboratory, Baylor College Of Medicine, Houston, Texas.

1994: 6 months of specialized training in the utilization of Trans-esophageal echocardiography in ICU/ CCU settings and the use of stress echocardiography testing. Echocardiography Lab. LBJ Hospital, University of Texas. Houston,Texas.

4/1996-7/1997: Associate Director, TIMI Angiographic Core Laboratory, West Roxbury VA Hospital, Boston, MA. Responsibilities include conducting and administrating research projects, angiographic data acquisition, data analysis, manuscript preparation and review for several multi-center clinical trials including:

-TIMI 10-B Trial (TNK-tPA vs tPA in acute myocardial infarction). -Restore Trial ( MK-383 + Heparin vs Heparin alone post PTCA). -Schneider” Free flow” perfusion balloon comparative trial. -IVAT( Intermediate Vessel Atherectomy Trial ). -Schneider wall stent in peripheral vessels Trial. -Schneider wall stents in coronary arteries Trial. 1996-1997: Sub- investigator in the MK 383 in Unstable angina/ Non Q wave MI Trial, West Roxbury VA medical center, Boston, Massachusetts 1997-date (Current work in progress): -Principle investigator of the study of Coronary Ectasia In Jordanians -Participated in a Phase 4 Multicenter study of Enoxaparin in acute coronary syndromes -Principle investigator of the “Study of Silent Ischemia in Jordanian Diabetics” -Principle investigator of the study of alternate –day statin use in Jordanians -Principle investigator of the study of Atorvastatin/ Amlodipine ( The GEMINI-AALA) Pfizer study in Jordan University hospital 2004

2003 -Founding Member of JCC-Jordan Collaborative Cardiologists group for research(Current projects listed at eArabDoctors.com)

Miscellaneous Courses:

Cardiac Auscultation Course, W. Proctor Harvey, MD. 1995, Houston, Texas. Intermedics Pacemaker Didactic Course, 1995. Texas Heart Institute, Peripheral Vascular Interventions`Course, 1995. Texas Heart Institute, High Risk Coronary Interventions`Course, 1995. Texas Heart Institute, Heart Transplant Symposium, 1995. Scimed Preceptor Training Program In Intravascular Ultrasound, 1996. Palmaz- Schatz Stent Certification Course 1996 Montreal Heart Institute, Interventional Cardiology Fellowship Course, 1996. Directional Coronary Atherectomy Basic Training Course (Guidant Inc), San Jose, California ,1997 Cardiology Review Course, Harvard Medical School, Boston, Massachusetts 1997 Numerous Meetings of AHA, ACC, TCT, ETC, PCR, ESC…etc

Bibliography:

Original Reports:- 1.Lozano P, Al-Mousa E, et al. Intra-aortic Thrombus Producing Embolic Arterial Vascular Disease. Images in Cardiovascular Medicine. Circulation. 1996;93:1471. 2.Dotani I, Dodge JT, Goel M, Al-Mousa EN, et al. Techniques in the Angiographic Analysis of Coronary Flow. J Interven Cardiol 1996;9:429-444 3.Gibson CM, Dodge JT Jr, Goel M, Al –Mousa EN, et al. Angioplasty Guide Wire Velocity: A new Simple Method to Calculate Coronary Blood Velocity and Flow. Am J Cardiol 1997 Dec 15, 80(12):1536-9 4.Al-Mousa EN, Dodge JT Jr, Rizzo M, et al. Thrombolysis in Myocardial Infarction Frame Count in Saphenous Vein Grafts. Am Heart J 1999 Feb;135(2Pt 1):323-8 .(This articles has the first published reference values for the normal TIMI Frame Counts in vein grafts). 5.Eyas Al-Mousa. Coronay Ectasia With In- Situ Thrombosis- A Case Report. Jordan Medical Journal. vol.37(1). May 2003. 6.Eyas Al-Mousa. Coronary Steal syndrome induced by unclipped LIMA branches -Case Report. Jordan Medical Journal , vol.37(2). November 2003. 7.Eyas Al-Mousa, , Yahya Ismail, Jamila AbuDheil, Munir Zaqa. Coronary Ectasia in Jordanians. Epidemiological features, prognosis, and a proposed new classification. Jordan Medical Journal vol.38(1). May 2004 8. Ayman J. Hammoudeh and Eyas Al-Mousa. Survey of Jordanian Physicians Management of Dyslipidemia in Patients with Cardiovascular Diseases and Diabetes. Jordan Medical Journal vol.38(1). May 2004 9.Randa Al-Ahmad, Azmi Mahafzah, Eyas Al-Mousa, Immunological Changes in Acute Myocardial Infarction. Saudi Medical Journal. 2004, vol. 25, no7, pp. 923-928

Jordan Collaborating Cardiology Group The Jordan Hyperlipidemia And Related Targets Studies

JCC/JoHARTS Publications

1. The JoHARTS investigators. Prevalence of conventional cardiovascular risk factors in Middle Eastern patients with coronary heart disease: The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 2). International Journal of Cardiology 2006;110:179-183. .

2. The JoHARTS investigators. Is dyslipidemia among diabetics in the Middle East different from that in the West? The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 3). Clinical Diabetes Middle East 2006;3:128-131

3. The JoHARTS investigators. Prevalence of conventional cardiovascular risk factors in Middle Eastern patients with coronary heart disease: The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 2). European Heart Journal 2005,26 (suppl):45.

4. The JoHARTS investigators. Is dyslipidemia among diabetics in the Middle East different from that in the West? The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 3). European Heart Journal 2005, 26 (suppl):495.

5. The JoHARTS investigators Dyslipidemia in 5000 Jordanians with and without coronary artery disease. The Jordan Hyperlipidemia And Related Targets Study (JoHARTS 3). In press

6. The JoHARTS investigators. Prevalence of low levels of high-density lipoprotein cholesterol (HDL-C) among 5000 Jordanians: The Jordan Hyperlipidemia And Related Targets Study (JoHARTS-4). Pan Arab Medical Journal, in press

7. The CAPRIS investigators. Is high-sensitive C-Reactive Protein an independent predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome? CRP and prognosis in acute coronary syndrome. European Heart Journal 2007; 28 (suppl): 595.

8. The CAPRIS investigators. Is high-sensitive C-Reactive Protein an independent predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome? CRP and prognosis in acute coronary syndrome. International Journal of Atherosclerosis, in press.

9. The SMART registry investigators. Are there gender disparities in the treatment of Non-ST elevation and ST-elevation acute coronary syndromes in the Middle East? Observations from the SMART registry. European Heart Journal 200;28 (suppl): 94.

10. JCC Group. Adherence to acute coronary syndrome therapy guidelines in a large Middle Eastern Population. Observations from the survey of management and assessment of coronary heart disease patients (SMART survey). European Heart Journal 2007; 28 (suppl):595.

11. The JCC group. Utilization of reperfusion therapy in the Myocardial Infarction Triggers and Onset in JoRdan (MINTOR) Study. International Journal of Cardiology 2007;122:156-157.

12. JoHARTS Investigation group. The Jordan Hyperlipidemia And Related targets Study (JoHARTS): Summary and Implications (part 1). in press.

13. JoHARTS Investigation group. The Jordan Hyperlipidemia And Related targets Study (JoHARTS): Summary and Implications (part 2). Middle East Medical Journal, in press.

14. JoHARTS Investigation group. The Jordan Hyperlipidemia And Related targets Study (JoHARTS): Summary and Implications (part 3). Middle East Medical Journal, in press.

15. JoHARTS and JCC Groups Investigators. Prevalence of diabetes mellitus in large acute coronary syndrome studies in a Middle Eastern country: The road to "GLORY". Clinical Diabetes Middle East Medical Journal, in press.

16. MINTOR Investigators. Triggers and time of onset of acute myocardial infarction in the Middle East. Myocardial INfarction Triggers and Onset in JoRdan (MINTOR) Study. International Journal of Cardiology, 01/12/2007; 122(2):156-7.

Review Articles:

1. C. Michael Gibson , Eyas N. Al-Mousa., and Thomas Levin. Characteristics of thrombolytic agents. Up to date. On CD-ROM. UpToDate Inc. 1997-date. 2. Gibson CM, Moynihan JL, Al-Mousa EN, Campsey M, Gandhi R, Murphy S, Mattson S, Ryan KA, Mesley R, Swanson J, Arshad MN, Marble SJ . Glycoprotein IIb/IIIa Receptor Inhibition in Interventional Cardiology. J Thromb Thrombolysis 1999 Jun;7(3):287-302 3. Eyas N. Al-Mousa. Diabetes and Coronary Artery Disease. Pan Arab Medical Journal volume 1, March 2004 4. Amar Salam and Eyas Al-Mousa. Resuscitation Update. ( accepted for publication, Jordan Medical Journal 4/ 2004) 5. Amar Salam and EyasAl-Mousa. The potential role of ximelagatran to become the anticoagulant of choice in Medicine. Expert opinion in pharmacotherapy. June 2004

Abstracts:

1. Gibson CM, Goel M, Dotani I, Rizzo MJ, McLean C, Martin NE, Al -Mousa EN, Marble SJ, Daley WL, Dodge T. The Post PTCA TIMI Frame Count and Mortality in RESTORE. Circulation 1996;94(8):I-85 2. Gibson CM, Dotani I, Goel M, McLean C, Rizzo MJ, Lis J, Martin NE, Marble SJ, Al-Mousa EN, Dodge T, Daley WL, Ross AM. Flow Improvement Following Intracoronary Stent Placement. Circulation 1996;94(8):I-453 3. Gibson CM, Daley WL, Rizzo MJ, McLean C, Martin NE, Dotani I, Al-Mousa EN Goel M, Marble SJ, Dodge JT. Flow Following PTCA For Acute MI. Circulation ;1996:94(8):I-670 4. Ryan KA, Rizzo MJ, McLean, Dotani I, Goel M, Marble SJ, Al-Mousa EN, Daley WL Dodge T. The Relationship Between Dissection Grade & Coronary Blood Flow as well as Other Angiographic Outcome After PTCA. JACC 1997;29(2):277 A 5. Gibson CM, Rizzo MJ, McLean, Dotani I, Goel M, Ryan KA, Marble SJ, Al-Mousa EN, Daley WL, Dodge T. The TIMI Frame Count and Restenosis : Faster is Better JACC 1997;29(2):201A 6. Gibson CM, Rizzo MJ, Ryan KA, McLean C, Marble SJ, Dotani I, Goel M, Al-Mousa EN, Daley WL, Dodge T. The Use of PTCA Guidewire to Measure Artery Length and the TIMI Frame Count to Measure Time as a Method of Calculating Coronary Velocity( Length /Time & Coronary Blood Flow). JACC 1997;29(2):18A 7. Dodge T, Goel M, Al-Mousa EN, Daley WL, Brown G, Gibson CM. In Vivo Validation of a New Three Dimensional Vector Model of Distance in Human Coronary Arteries. JACC 1997;29(2):35A 8. Gibson CM, Marble SJ, Rizzo MJ, Ryan KA, McLean C, Sparano AM, Moynihan J, Al-Mousa EN, Dodge T. Pooled Analysis of Primary Stenting in Acute MI in 1,357 Patients. JACC 1997;29(2):18A 9. Gibson CM, Rizzo MJ, Ryan KA, McLean C, Sparano AM, Moynihan J, Al-Mousa EN, Dodge T. Multivariable Model of Coronary Flow at 90 Minutes Following Thrombolysis. Circulation 1997;96(8):I-340 10. Al-Mousa E, Cannon L, Senior D, Feit F, Attubato M, Rosenberg J, O’Donell C, Ryan K, Sparano AM, Gibson CM. Directional Atherectomy Normalizes Guide wire Velocity in the Intermediate Vessel Atherectomy Trial ( IVAT). Circulation 1997;96(8):I-648 11. Dodge T, Sparano AM, Ryan KA, McLean C, Ralston A, Al-Mousa EN, Daley WL. Best Angiographic Views to Minimize Coronary Artery Foreshortening. Circulation 1997;96(8):I-78

Grand Rounds and invited Presentations:'

1. Platelet Glycoprotein IIb/IIIa in Cardiology. Cardiology Grand Rounds, West Roxbury VA Medical center, Harvard Medical School, Boston, Massachusetts, USA March 1997 2. Valvular Heart Disease. Speciality Hospital, Amman, Jordan 1998. 3. Update on Acute MI. Jordan University Hospital medical grand round. 1998 4. State of the art on Lipid therapy. Jordan University Hospital medical grand round. 1999 5. Contemporary Management of Acute Coronary Syndromes. Saddam Heart Center. Baghdad, Iraq 1999 6. Statins’ Overview. Bristol Myers Squib invited lecturer. Jordan Lipid and hypertension society. Amman, Jordan 2000. 7. Heart Protection Study. MSD invited lecturer. Amman, Jordan 2001 8. Statins: from bench to bedside. Bristol Myers Squib symposium- keynote speaker. First Pan Arab internal medicine conference. Amman , Jordan 2002 9. NCEP 3 Guidelines- New Perspectives. Experts’ Meeting-Novartis Symposium. Beirut, Lebanon 2002 10. Hypertension Management, Combination Therapy. Novartis Symposium. Dead –Sea, Jordan 2002 11. “LIPS” Study. Novartis Invited Lecture. Amman, Jordan 2002 12. Survey of Jordanian Physicians’ Attitude towards Dyslipidemia. Sixth Jordanian Cardiac Society meeting. Amman, Jordan. October 2002 13. Overview of ARBs. Novartis invited lecturer. Sharm Al-Sheikh, Egypt. February 2003 14. “PROSPER” study. Bristol Myers Squib invited lecturer. Amman, Jordan. March 2003 15. Quality Control of Blood Pressure. BoehrInger Ingelheim invited lecturer. Amman, Jordan. March 2003. Petra, Jordan. March and April 2004 16. Hypertension: clinical aspects and tips for management. Astra-Zeneca invited lecturer. Petra, Jordan. May 2003 17. “Prove It” Study, Bristol Myers Squib invited lecturer. Amman, Jordan. March 2004 18. Founder and Moderator of the Monthly City Wide Cardiac Catheterization Conference 8 / 2003- present. Amman – Jordan 19. “LIFE” Study, Losartan Launch Symposium. Private health care sector lecture. Khartoum, Sudan. March 2004 20. “EUROPA” study. Servier Symposium- keynote speaker. Second Pan Arab Internal Medicine Conference. Amman, Jordan. April 2004 21. Coronary Ectasia in Jordanians. Seventh Jordanian Cardiac Society meeting. Amman, Jordan. June 2004 22. The VALUE study, Novartis invited lecturer. Amman, Jordan. 10/2004 23. The Moses study. Solvay invited lecturer. Amman, Jordan. 10/2004 24. Overview of Modern Thrombolytic Therapy. Nairobi Hospital. Nairobi, Kenya. 10/2004 25. Hypertension Overview. Kenyatta Hospital Medical Grand Round. Nairobi, Kenya. 10/2004 26. Sustained control of Blood Pressure. Micardis Plus Launch Symposium-Keynote Speaker. Nairobi, Kenya. 10/2004 27. Overview of ARBs. Qaryounes University. Benghazi, Libya. 2/2005 28. The Moses study. Solvay invited lecturer. Beirut. Lebanon 3/2005 and 3/ 2006 29. Clarity and Commit Trials. Sanofi- Aventis/Jordan Internal Medicine Society invited lecturer. Al - Istiklal Hospital . Amman. Jordan 12/2005 30. Clarity and Commit Trials. Sanofi- Aventis invited lecturer. Cairo. Egypt. 12/2005 31. Hypertension in Pregnancy. Jordan Obstetrics’ Society Lecture. Amman, Jordan 12/2005 32. Overview of Recent Statin Trial, Astra- Zeneca invited lecturer. Amman, Jordan. 4/2006 33. ASCOT Trial. A new way to target hypertension. Pfizer invited lecturer. Amman, Jordan. 4/2006. 34. JOHARTS 4 study. Eighth Jordanian Cardiac Society meeting. Amman, Jordan. June 2006 35. Review of Valsartan evidence. Novartis Diovan Launch Symposium-Keynote Speaker. Damascus and Allepo. Syria 12/2006 36. Aliskiren, a new Renin inhibitor. Pre-launch symposium . Novartis Jordan. Dead sea. 11/2007. 37. Calcium Channel Blockers revisited- Jerusalem drug company lecture-Amman, Jordan 2/2008‏ 38. DES Overview- Focus on biodegradable polymers technology- Biomatrix stent,, Biosensors invited lecture. 3/2008. 39. New pathways in hypertension. Novartis invited speaker. Beijing, China,4/2008 40. CLOPLAV pharmacodynamic study, first study in Jordan with head to head comparison 41. Numerous lectures for special courses on ACLS, critical care, cardiac diseases in pregnancy, preoperative cardiac assessment... 1997-present.